SKLB325 (SKLB 325) is a potential inhibitor for JMJD6 with Kd of 0.755 uM by SPR assays, biochemical IC50 of 0.78 uM.
SKLB325 suppresses proliferation, induces apoptosis in ovarian cancer cells, inhibits angiogenesis in HUVECs, and inhibits migration in ovarian cancer cells and HUVECs in vitro.
SKLB325 upregulates the expression of p53 and its downstream effectors at both the mRNA and protein levels in vitro.
SKLB325 exhibits strong therapeutic effects on intraperitoneal dissemination xenograft mouse models, upregulates the expression of p53 as well as its downstream effectors at the protein level in vivo.
